A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma-Reference-Cited by-同舟云学术

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma

Published:2014-03-06 Issue:10 Volume:123 Page:1461-1469
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Richardson Paul G.¹,Xie Wanling¹,Jagannath Sundar²,Jakubowiak Andrzej³,Lonial Sagar⁴,Raje Noopur S.⁵,Alsina Melissa⁶,Ghobrial Irene M.¹,Schlossman Robert L.¹,Munshi Nikhil C.¹,Mazumder Amitabha⁷,Vesole David H.⁸,Kaufman Jonathan L.⁴,Colson Kathleen¹,McKenney Mary¹,Lunde Laura E.¹,Feather John¹,Maglio Michelle E.¹,Warren Diane¹,Francis Dixil⁴,Hideshima Teru¹,Knight Robert⁹,Esseltine Dixie-Lee¹⁰,Mitsiades Constantine S.¹,Weller Edie¹,Anderson Kenneth C.¹

Affiliation:

1. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;

2. Tisch Cancer Institute, Mount Sinai Medical Center, New York, NY;

3. Division of Hematology/Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI;

4. Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA;

5. Center for Multiple Myeloma, Massachusetts General Hospital, Boston, MA;

6. Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center, Tampa, FL;

7. Department of Medicine, New York University Comprehensive Cancer Center, New York, NY;

8. Multiple Myeloma Division, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ;

9. Oncology Research and Development, Celgene, Inc., Summit, NJ; and

10. Oncology Clinical Research, Millennium: The Takeda Oncology Company, Cambridge, MA

Abstract

Key Points Lenalidomide-bortezomib-dexamethasone resulted in partial response or better in nearly two-thirds of relapsed/refractory myeloma patients. The regimen had substantial activity despite high rates of prior bortezomib/thalidomide and regardless of poor prognostic characteristics.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/123/10/1461/1374631/1461.pdf

Reference50 articles.

1. Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010.;Brenner;Haematologica,2009

2. Improved survival in multiple myeloma and the impact of novel therapies.;Kumar;Blood,2008

3. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.;Richardson;N Engl J Med,2005

4. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.;Richardson;Blood,2007

5. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.;Dimopoulos;N Engl J Med,2007

Cited by 167 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative effectiveness of lenalidomide/dexamethasone-based triplet regimens for treatment of relapsed and/or refractory multiple myeloma in the United States: An analysis of real-world electronic health records data;Current Problems in Cancer;2024-06

2. Proteasome Inhibitors in Multiple Myeloma;Hematology/Oncology Clinics of North America;2024-04

3. Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology;Journal of the National Comprehensive Cancer Network;2023-12

4. Proteasome inhibition in combination with immunotherapies: State-of-the-Art in multiple myeloma;Blood Reviews;2023-09

5. Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma;Haematologica;2023-08-24